We previously reported on the partial prevention of experimental shunt-induced pulmonary arterial hypertension (PAH) by the nonselective endothelin (ET) ET-A/ET-B receptor antagonist bosentan. As the respective roles of the ET-A and ET-B receptor signaling in the pathobiology of the disease remain undefined, we investigated the effects of selective ET-A receptor blockade by sitaxsentan in the same early stage PAH model. Twenty-one 3-wkold piglets were randomized to placebo or sitaxsentan therapy (1.5 mg/kg/d), after anastomosis of the left subclavian artery to the pulmonary arterial trunk or after a sham operation. Three months later, the animals underwent a hemodynamic evaluation, followed by pulmonary tissue sampling for morphometry and real-timequantitative-PCR for ET-1, angiopoietin-1, and bone morphogenetic receptor (BMPR) signaling molecules. Three months of left to right shunting induced an increase in pulmonary vascular resistance (PVR) and medial thickness, an overexpression of ET-1, ET-B receptor, and angiopoietin-1, and a decreased expression of BMPR-2 and BMPR-1A. Pretreatment with sitaxsentan prevented shunt-induced increase in PVR and decreased medial thickness by 64%. Sitaxsentan therapy completely prevented the decreased expression of BMPR-2 and limited the overexpression of ET-1, ET-B and angiopoietin-1, and the decreased expression of BMPR-1A. In conclusion, selective ET-A receptor blockade partially prevents shunt-induced PAH. T he pathogenesis of PAH remains incompletely understood (1,2). Because of the therapeutic efficacy of ET receptor blockers, and because BMPR-2 mutation is associated with a high risk to develop the disease, the ET and BMP signaling pathways are each thought to play a major role in the pathobiology of PAH (1,2). We previously reported on a left-toright shunt-induced pulmonary hypertension in piglets as a model for the study of early stage PAH (3-5). This model is characterized by an increase of PVR, medial hypertrophy of the small arterioles, and overexpression of ET-1, ET-B, and Ang-1, together with decreased expressions of BMPR-2 and BMPR-1A (4,5). Thus, both endothelin and BMP signaling are involved in the early stages of PAH (4,5).
T he pathogenesis of PAH remains incompletely understood (1, 2) . Because of the therapeutic efficacy of ET receptor blockers, and because BMPR-2 mutation is associated with a high risk to develop the disease, the ET and BMP signaling pathways are each thought to play a major role in the pathobiology of PAH (1, 2) . We previously reported on a left-toright shunt-induced pulmonary hypertension in piglets as a model for the study of early stage PAH (3) (4) (5) . This model is characterized by an increase of PVR, medial hypertrophy of the small arterioles, and overexpression of ET-1, ET-B, and Ang-1, together with decreased expressions of BMPR-2 and BMPR-1A (4, 5) . Thus, both endothelin and BMP signaling are involved in the early stages of PAH (4, 5) .
ET-1 interacts with ET-A and the ET-B receptors on pulmonary vascular smooth muscle cells to induce constriction and proliferation (6 -9) , and with ET-B receptors on pulmonary artery endothelial cells for nitric oxide (NO) modulation of endothelin synthesis (10) , endothelin clearance (11) , and release of NO and prostacyclin (12) . The ET-B receptor is overexpressed in overcirculation-induced PAH models (4, 5, 13) . However, the pathogenetic role of the ET-B receptor in PAH remains undefined, as both the nonselective ET-A/B receptor blocker bosentan and the selective ET-A blockers sitaxsentan and ambrisentan similarly improved PAH patients in randomized controlled trials (14 -16) . We observed that bosentan therapy prevented the increase in PVR and approximately 70% of pulmonary arteriolar remodeling in growing piglets with a left-to-right shunt-induced PAH (4). We hypothesized that sitaxsentan, a highly selective ET-A receptor blocker (17) , might be even more effective in preventing early PAH by allowing for ET-B receptor-mediated ET clearance and antagonistic prostacyclin and NO release.
MATERIALS AND METHODS
Twenty-one piglets 18 Ϯ 1 d old and weighing 5.4 Ϯ 0.2 kg were included in this study. These experiments were conducted in agreement with the guide for the care and use of laboratory animals of the U.S. National Institutes of Heath, and were approved by the committee on the care and use of animals in research of Brussels Free University School of Medicine. The animals were randomized to a sham operation (n ϭ 7) or to an anastomosis between the left innominate artery and the pulmonary arterial trunk as previously reported (3) (4) (5) , followed by randomization to sitaxsentan 1.5 mg/kg/d (n ϭ 7) or placebo (n ϭ 7) administered orally with food for 3 mo.
Hemodynamic evaluation. As previously reported (3) (4) (5) , the animals were anesthetized and equipped with catheters and an ultrasonic flow probe on the pulmonary artery for measurement of Ppa m , Ppao, Psa m , Q, pulmonary arterial flow, and blood gases. PVR was defined by multipoint point (Ppa m -Ppao)/Q plots obtained by rapid inflation of the inferior vena cava balloon (3) (4) (5) .
Hemodynamic and blood gases measurements were obtained with animals in steady-state conditions for 60 min, after shunt closure. After the measurements, the animals were killed and pulmonary tissue samples were harvested and snap frozen in liquid nitrogen and stored at -80°C or, after overnight fixation, embedded in paraffin.
Morphometry. Pulmonary arterial morphometry was performed as reported previously (4, 5) . MT was related to arterial size with the following formula: %MT ϭ (2 ϫ MT)/(ED ϫ 100), where ED means external diameter.
Real time quantification PCR. Pulmonary tissue mRNA levels were measured by SYBR Green RTQ-PCR for ET-1 and Ang-1/BMPR-2 pathways with primers previously reported (4, 5) . To ensure the quality of the measurements, both negative and positive controls were systematically included in double, in each plate. The statistical analysis of the RTQ-PCR results was done using the ⌬Ct value (Ct gene of interest -Ct reporter gene). Relative gene expression was obtained by ⌬⌬Ct methods (⌬Ct sample -⌬Ct calibrator) using the sham group as a calibrator, for comparison of every unknown samples genes expression levels. The conversion between ⌬⌬Ct and relative gene expression levels is: Fold induction ϭ 2 -⌬⌬Ct (18) . For the purpose of comparison, we measured with the same methods mRNA content for Ang-1, BMPR-1A, and BMPR-2 in lung tissue of sham, placebo-, and bosentantreated of previously reported piglets (4) .
RIA. Systemic arterial plasma ET-1 was measured by RIA after extraction as previously described (4, 5) , using commercially available antibodies and tracers iodinated and HPLC purified in our laboratory.
Immunohistochemistry. The immunohistochemistry analysis was performed as previously reported (4,5) with rabbit MAb to ET-1 (1/100 dilution) prepared in our laboratory. A mean OD, which relates to immunohistochemical staining intensity, was calculated for 20 pulmonary arteries of Ͻ500 m.
Statistical analysis. Values are reported as mean Ϯ SEM. Effects of the shunt and drugs were analyzed by a repeated measures ANOVA. When the F ratio of the ANOVA reached a p Ͻ 0.05 critical value, Scheffe post hoc tests were performed to compare specific situations (19) . Correlations were calculated via a linear regression analysis (19) .
RESULTS
Weight averaged 40 kg and was not different in the three study groups. Arterial blood gases and hematocrits were normal and not different in the three study groups. The ratio of pulmonary to systemic flow before closure of the shunt was 1.9 ϩ 0.1 in the placebo group and 1.8 ϩ 0.1 in the sitaxsentan group (p ϭ NS).
Chronic systemic-to-pulmonary shunting increased Ppa m , PVR, Ppao, Ees, and Ea without change in HR, Q, Psa m , or the ratio of Ees to Ea ( Table 1) . The (Ppa m -Ppao)/Q relationships were shifted to higher pressures with an increase in slope ( Fig. 1 ). There was an increase in pulmonary arterial MT, and this effect was most pronounced in the smallest arterioles (Fig. 2) . Plasma ET-1 increased, from 2.0 Ϯ 0.1 pg/mL in the sham operated controls to 3.8 Ϯ 0.5 pg/mL in placebo-treated animals (p Ͻ 0.05).
Sitaxsentan therapy prevented the increases in Ppa m , Ppao, PVR, Ees, and Ea (Table 1 ) and partially prevented the shift to higher pressure of Ppa m -Ppao/Q relationships (Fig. 1) . Sitaxsentan reduced the increase in pulmonary arterial MT by an average of 64% (Fig. 2) . In the sitaxsentan-treated animals, plasma ET-1 was at 2.4 Ϯ 0.1 pg/mL (p ϭ NS versus sham-operated controls).
As illustrated in Figure 3 , systemic-to-pulmonary shunting increased gene expressions for ET-1, ET-B receptor, ET converting enzyme (ECE-1), and Ang-1, decreased gene expres- In previously reported piglets (4), the nonselective ET-A/B receptor blocker bosentan decreased the changes in gene expressions for Ang-1, BMPR-1A ,and BMPR-2 without returning any of them to normal (Fig. 3) .
As illustrated in Figure 4 , chronic left-to-right shunting increased pulmonary arterial immunostaining for ET-1, and this was reduced by sitaxsentan. There was a significant correlation between lung protein content of ET-1 and the percentage of MT of the smallest pulmonary arterioles.
DISCUSSION
The present results show that administration of sitaxsentan, a selective ET-A receptor antagonist, prevents overcirculation-induced PAH in piglets, by limiting hemodynamic and morphometric changes together with an improvement in dysfunctional ET-1 and BMP signaling pathways.
Chronic systemic to pulmonary shunting in growing piglets has been previously reported to be a realistic model for congenital cardiac shunt-induced PAH (3) (4) (5) 20) . The piglet pulmonary circulation is exquisitely reactive, allowing for development in several weeks of high flow-induced hemodynamic and morphologic changes that would require decades in man (20) . In the present study, 3 mo of aorta-pulmonary shunting in growing piglets caused severe pulmonary hypertension, with mean Ppa between 30 and 40 mm Hg at a normal cardiac output, and pulmonary arteriolar medial hypertrophy, 
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in keeping with previous reports (3) (4) (5) . This corresponds to severe, though early and still reversible, disease (10), making this model suitable for the investigation of initial biologic changes. The ET system is activated in patients with advanced PAH, who present with increased circulating levels of ET-1 (21) (22) (23) and an overexpression of lung tissue ET-1 (23) . In overcirculation-induced PAH, there is also an overexpression of the ET-B receptor, while the expression of the ET-A receptor remains unchanged (4, 5, 13) . In hypoxic pulmonary hypertension, both the ET-A and the ET-B receptors are overexpressed, and lung tissue ET-1 mRNA and circulating ET-1 are increased (24) . In monocrotaline-induced pulmonary hypertension, circulating ET-1 is increased, but lung tissue ET-1 protein and mRNA are decreased (25) . Thus, measurements of lung tissue mRNA and protein for ET-1 and its receptors may not always accurately reflect changes in the functional state of this signaling pathway in the development and perpetuation of pulmonary hypertension.
The development of potent, long-acting, and orally available nonselective and selective ET receptor antagonists has made it possible to explore the function of ET-1 receptor signaling in experimental and clinical pulmonary hypertension. Both nonselective ET-A/B and selective ET-A receptor blockers prevent and reverse hypoxic as well as monocrotaline-induced pulmonary hypertension (24 -28) , suggesting that the ET-A receptor is the major determinant of ET-1-mediated pathobiological changes in these two types of pulmonary hypertension. An alternative explanation would be that the endothelial and smooth muscle cell ET-B receptor functions remain balanced in PAH, with reciprocal cancelling of proand antiproliferative and vasoconstrictive effects. In a face-toface comparison of the effects of selective ET-A and nonselective ET-A/B receptor blockade in monocrotaline-induced pulmonary hypertension, both treatments appeared equally effective in decreasing PVR, although there might have been an improvement in survival in the nonselective ET-A/B blocker group, possibly related to a lesser degree of right ventricular remodeling (29) . However, in another study on monocrotaline-induced pulmonary hypertension, a more selective ET-A blocker and a nonselective ET-A/B blocker similarly decreased right ventricular systolic pressure and hypertrophy, which were aggravated by a selective ET-B receptor blocker (30) . On the other hand, whether a limitation of right ventricular remodeling is beneficial in pulmonary hypertension is not established, as myocardial hypertrophy contributes to the adaptation of systolic function to increased afterload (31) .
In the present experiments, the prevention of the increase in PVR, the remodeling of pulmonary arterioles, and associated biologic changes was similar to previously reported with bosentan (4) or sildenafil (5) . In the same experimental conditions, the increase in small arteriole medial thickness was inhibited by 50% by sildenafil, 70% by bosentan, and 65% by sitaxsentan, whereas the increase in Ppa at a cardiac output of 4 L/min was limited to 10% by sildenafil and bosentan and to 30% by sitaxsentan. This a posteriori comparison could suggest that the three interventions would be equally effective in the prevention of remodeling, but that sildenafil and bosentan could be more effective than sitaxsentan in the inhibition of vasoconstriction. It is possible that in early overcirculationinduced PAH, the ET-B receptor would contribute to ET-1-induced vasoconstriction (32) . However, because of a posteriori comparisons of effects in different studies, it is impossible from our data to conclude that any of the three drugs would be superior or inferior to the others in the prevention of shuntinduced PAH.
In overcirculation-induced PAH in lambs, selective ET-A receptor blockade has been reported to decrease PVR, without effect on arteriolar MT, without associated changes in plasma ET-1 or lung tissue preproendothelin-1, ET converting enzyme, and ET-A or ET-B receptor protein levels (33) . It has to be noted that, in that study, pulmonary arteriolar MT was not increased compared with controls, suggesting very early purely vasospastic PAH (33) , difficult to compare with more advanced overcirculation-induced PAH in piglets, where there is both vasoconstriction and remodeling (3) .
The present results confirm that overcirculation-induced early PAH in piglets is associated with an overexpression of Ang-1 and a decreased expression of BMPR-1A (5), like reported in patients with advanced forms of severe pulmonary hypertension (34) . They also confirm the early occurrence of a decreased expression of BMPR-2 (5), previously shown by semi-quantitative immunostaining in both idiopathic and congenital cardiac shunt induced PAH (35) . In addition, in the present study, the gene expressions for ET-1, Ang-1, BMPR-1A, and BMPR-2 were all correlated to pulmonary arteriolar remodeling, which may suggest a positive interaction between ET, Ang-1, and BMP signaling in early PAH. It is of interest that the preventive application of therapies aimed at the restoration of endothelial vasodilator/constrictor equilibrium, either by the inhibition of phosphodiesteras-5 by sildenafil (5) by inhibition of ET-A/B receptors by bosentan (4), or by inhibition of ET-A receptors by sitaxsentan, tend to return the expressions of Ang-1, BMPR-2, and BMPR-1A to normal. However, the nature of the interactions between these different pathways remains incompletely understood.
In the present study, right ventricular Ees, a loadindependent index of contractility, increased in proportion to Ea, and that right ventriculoarterial coupling, estimated by a Ees/Ea ratio, remained unchanged, with and without treatment with sitaxsentan. This result confirms previous observations in the same model with preventive administration of bosentan. In patients with PAH, right ventricular Ees is also increased, but Ees/Ea is decreased, indicating a decoupling of right ventricular function and right heart failure (31). In overcirculationinduced PAH in piglets, 3 mo of shunting does not appear sufficient to decouple the right ventricle from the hypertensive pulmonary circulation, and ET-1-receptor signaling does not appear to play a role in right ventricular systolic function adaptation.
In conclusion, the present study shows that sitaxsentan, a highly-selective ET-A receptor antagonist, partially prevents overcirculation-induced pulmonary hypertension in piglets, with a decrease in pulmonary vascular tone and in remodeling, and reverses the associated decrease in BMPR-2 expression, 287 SITAXSENTAN IN PULMONARY HYPERTENSION suggesting a significant participation of both endothelin receptor and BMP receptor signaling in the early stages of shunt-induced PAH.
